Site maintenance Wednesday, November 13th, 2024. Please note that access to some content and account information will be unavailable on this date.
Skip to main content
Full access
Influential Publication
Published Online: 25 January 2022

Sonication of the Anterior Thalamus With MRI-Guided Transcranial Focused Ultrasound (tFUS) Alters Pain Thresholds in Healthy Adults: A Double-Blind, Sham-Controlled Study

Abstract

Background:

Transcranial focused ultrasound (tFUS) is a noninvasive brain stimulation method that may modulate deep brain structures. This study investigates whether sonication of the right anterior thalamus would modulate thermal pain thresholds in healthy individuals.

Methods:

We enrolled 19 healthy individuals in this three-visit, double-blind, sham-controlled, crossover trial. Participants first underwent a structural MRI scan used solely for tFUS targeting. They then attended two identical experimental tFUS visits (counterbalanced by condition) at least one week apart. Within the MRI scanner, participants received two, 10-min sessions of either active or sham tFUS spread 10 min apart targeting the right anterior thalamus [fundamental frequency: 650 kHz, Pulse repetition frequency: 10 Hz, Pulse Width: 5 ms, Duty Cycle: 5%, Sonication Duration: 30s, Inter-Sonication Interval: 30 s, Number of Sonications: 10, ISPTA.0 995 mW/cm2, ISPTA.3 719 mW/cm2, Peak rarefactional pressure 0.72 MPa]. The primary outcome measure was quantitative sensory thresholding (QST), measuring sensory, pain, and tolerance thresholds to a thermal stimulus applied to the left forearm before and after right anterior thalamic tFUS.

Results:

The right anterior thalamus was accurately sonicated in 17 of the 19 subjects. Thermal pain sensitivity was significantly attenuated after active tFUS. The pre-post x active-sham interaction was significant (F(1,245.95) = 4.03, p = .046). This interaction indicates that in the sham stimulation condition, thermal pain thresholds decreased 1.08°C (SE = 0.28) pre-post session, but only decreased .51°C (SE = 0.30) pre-post session in the active stimulation group.

Conclusions:

Two 10-min sessions of anterior thalamic tFUS induces antinociceptive effects in healthy individuals. Future studies should optimize the parameter space, dose and duration of this effect which may lead to multi-session tFUS interventions for pain disorders.
(Appeared originally in Brain Stimulation 2020; 13:1805–1812)
Reprinted with permission from Elsevier

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

History

Received: 11 May 2020
Revision received: 12 October 2020
Accepted: 12 October 2020
Published in print: Winter 2022
Published online: 25 January 2022

Keywords

  1. Focused ultrasound
  2. fus
  3. tfus
  4. lifup
  5. Low intensity focued ultrasound
  6. Pain
  7. Thalamus
  8. MRI
  9. Sonication

Authors

Details

Bashar W. Badran [email protected]
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Kevin A. Caulfield
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Sasha Stomberg-Firestein
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Philipp M. Summers
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Logan T. Dowdle
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Matt Savoca
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Xingbao Li
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Christopher W. Austelle
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
E. Baron Short
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Jeffrey J. Borckardt
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Norman Spivak
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Alexander Bystritsky
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Mark S. George
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; University of California, Los Angeles, Los Angeles, CA, USA; BrainSonix Corporation, Sherman Oaks, CA, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA.

Notes

Corresponding author. Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, USA. E-mail address: [email protected] (B.W. Badran).

Competing Interests

AB is employed by BrainSonix, which manufactures the ultrasound device. He holds patents in this area. BWB owns minority stake in Bodhi NeuroTech Inc, which manufactures meditation enhancing devices and holds patents in this area. No other authors have any other conflicts.

Funding Information

Funding for this study was provided by the Tiny Blue Dot Foundation (TBD).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Focus

PPV Articles - Focus

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share